4,626 Johnson & Johnson $JNJ Shares Purchased by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,616 shares of the company’s stock after purchasing an additional 4,626 shares during the quarter. Johnson & Johnson accounts for approximately 0.7% of Soltis Investment Advisors LLC’s investment portfolio, making the stock its 23rd largest holding. Soltis Investment Advisors LLC’s holdings in Johnson & Johnson were worth $14,459,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Founders Financial Securities LLC increased its holdings in Johnson & Johnson by 8.4% in the 3rd quarter. Founders Financial Securities LLC now owns 25,378 shares of the company’s stock worth $6,719,000 after buying an additional 1,970 shares during the period. ERn Financial LLC lifted its stake in Johnson & Johnson by 10.6% during the 3rd quarter. ERn Financial LLC now owns 919 shares of the company’s stock valued at $243,000 after acquiring an additional 88 shares during the period. Crew Capital Management Ltd lifted its stake in Johnson & Johnson by 7.4% during the 3rd quarter. Crew Capital Management Ltd now owns 9,957 shares of the company’s stock valued at $2,636,000 after acquiring an additional 686 shares during the period. Choreo LLC boosted its holdings in shares of Johnson & Johnson by 1.5% in the 3rd quarter. Choreo LLC now owns 142,622 shares of the company’s stock valued at $37,758,000 after acquiring an additional 2,052 shares during the last quarter. Finally, Blueprint Financial Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $2,793,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 64,515 shares of company stock valued at $17,271,766 over the last ninety days. Corporate insiders own 0.16% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
• Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
• Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
• Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
• Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
• Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation

Johnson & Johnson Stock Down 0.7%

Johnson & Johnson stock opened at $273.39 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The stock has a market capitalization of $658.13 billion, a PE ratio of 41.42, a price-to-earnings-growth ratio of 2.70 and a beta of 0.21. The business has a 50 day simple moving average of $265.74 and a 200-day simple moving average of $246.94. Johnson & Johnson has a 12 month low of $185.12 and a 12 month high of $282.02.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the firm posted $2.80 EPS. The business’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Sanford C. Bernstein set a $270.00 target price on shares of Johnson & Johnson in a research report on Thursday, October 15th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $282.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Erste Group Bank downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Finally, Argus set a $300.00 price objective on Johnson & Johnson in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $275.92.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.